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Abstract 
 
 
 
 
 
 
 
Left ventricular non-compaction cardiomyopathy is a genetic disorder 
characterized by the presence of two myocardial layers with numerous prominent 
trabeculations and deep inter-trabecular recesses that communicate with the 
ventricular cavity. The diagnosis is often challenging because excessive trabeculations 
may also be a normal finding in performance athletes and black people.  
Echocardiography is the gold standard for diagnosis of this condition, but other 
useful diagnostic techniques may include cardiac magnetic resonance imaging, 
computed tomography, and contrast ventriculography. Moreover, newer 
echocardiographic methods such as three-dimensional imaging and speckle tracking 
analysis promise to improve the diagnosis of left ventricular non-compaction 
cardiomyopathy. The purpose of this paper is to review the pathogenesis, diagnosis, 
and management of this disease. 
 
Acne conglobata is a rare, severe form of acne vulgaris characterized by the presence of comedones, 
papules, pustules, nodules and sometimes hematic or meliceric cr sts, l cated on the face, trunk, neck, arms 
and buttocks.  
 
Case Report 
We report the case of a 16 year old Caucasian female patient from the urban area who addressed our 
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Introduction 
Left ventricular non-compaction (LVNC) or ‘spongy 
myocardium’ is a congenital disorder characterized by 
the presence of a thin epicardial layer and an excessively 
trabeculated endocardial layer. This particular spongious 
aspect of the myocardium was first described more than 
eight decades ago in association with aortic atresia and 
coronary-to-chamber fistula during the autopsy of a 
newborn with complex congenital abnormalities (1). The 
introduction of two-dimensional echocardiography 
facilitated the evaluation of left ventricle (LV) anatomy 
and continuously increased the number of cases 
diagnosed. In 1984 Engberding described the presence 
of ‘sinusoids’ within the LV, but it was not until 1990 
that the first diagnostic echocardiographic criteria of 
LVNC were proposed and terminology was established 
(2, 3). 
Despite current developments in cardiac imaging 
and genetic diagnostic techniques, it is yet controversial 
whether left ventricular non-compaction cardiomyopathy 
is a distinct cardiomyopathy or a morphologic feature 
shared by different types of cardiomyopathy (4). Recent 
data, for example, have found that a significant 
proportion of asymptomatic individuals free from 
cardiovascular disease met all currently used magnetic 
resonance imaging (MRI) diagnostic criteria for LVNC, 
suggesting that the condition is an anatomical phenotype 
rather than a distinct cardiomyopathy (5). To add to the 
controversy, non-compacted myocardium has been 
categorized as unclassified cardiomyopathy by the 
European Society of Cardiology (ESC) in the recently 
published report on the definition and classification of 
cardiomyopathies (6), whereas the American Heart 
Association (AHA) classifies it as a primary genetic 
cardiomyopathy (7) (Figure 1). 
 
 
 
Figure 1. Classification of primary (predominantly 
involving the heart) cardiomyopathies according to 
ESC and AHA. AHA, American Heart Association; 
ARVD, Arrythmogenic right ventricle dysplasia; CM, 
cardiomyopathy; DCM, dilated cardiomyopathy; ESC, 
European Society of Cardiology; HCM, hypertrophic 
cardiomyopathy; LVNC, left ventricle non-
compaction. 
Discussion 
Prevalence 
The prevalence of LVNC in the general population 
remains unknown, although in echocardiographic series 
it is reported around 0.14-1.3%. Isolated ventricular non-
compaction has an incidence of 0.01-0.26% in 
observational studies (8, 9). In a pediatric population 
with any type of primary cardiomyopathy, LVNC was 
diagnosed in 9.2%, being the most frequent form after 
dilated and hypertrophic cardiomyopathy (10). Left 
ventricular non-compaction in children is often 
associated with anatomical abnormalities such as septal 
or atrial defects, congenital aortic stenosis, and aortic 
coarctation, although studies have failed to demonstrate 
any direct relation among these conditions. Furthermore, 
non-compacted myocardium has been found in patients 
with neuromuscular diseases such as Becker muscular 
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dystrophy, Friedrich ataxia, myotonic dystrophy, or 
mitochondrial diseases. 
Nevertheless, published rates may well 
underestimate the prevalence of LVNC. Better 
echocardiographic imaging and LVNC awareness will 
likely lead to a better recognition of this pathology. 
Pathogenesis 
The mechanisms of non-compaction are not yet fully 
understood. The main morphogenetic anomaly is 
represented by the cessation of compaction of ventricular 
endomyocardium during intrauterine development. If 
this process does not progress normally, the LV 
develops as a two-layered structure, with a thick non-
compacted endocardial layer and a thin compact 
epicardial layer, mostly observed in the inferior, lateral 
and apical segments. 
 During myocardial embryonic development, the 
muscular fibers lose their connections, resulting in a 
weak fiber network, with recesses that connect the 
myocardial wall with the ventricular cavity. Only in the 
5th or 6th week of gestation does this fiber and 
intertrabecular recesses network begin the compaction 
process, starting from the base towards the apex and 
from the endocardium to the epicardium. This process 
implies the secretion of endothelial growth factors, such 
as neuregulins and angiopoietins. For reasons still 
unknown, this process ceases in patients with LVNC, 
resulting in a thick non-compacted endomyocardial layer 
with prominent trabeculae and deep recesses that 
communicate with the LV cavity and a thin compacted 
epicardial layer.  This embryologic hypothesis is 
supported by the fact that LVNC is frequently associated 
with other congenital heart abnormalities (11). Other 
theories suggest that ventricular non-compaction might 
be the consequence of a cardiac neuropathy or the result 
of a malfunction of gap junctions (12). 
The trabecular phenotype in LVNC can also develop 
during adulthood as a response to left ventricular 
overload. In one large-scale study, excessive 
trabeculation of the LV was found in up to 18% of 
highly trained athletes. Nonetheless, only 0.9% of these 
athletes also presented with ECG changes and 
echocardiographic signs of systolic function depression 
(13). Development of the ‘de novo’ hypertrabeculation 
has been observed in more than 25% of pregnant women 
and is related to LV overload and mechanisms of 
physiological adaptation to pregnancy. A similar 
anatomical aspect was described in patients suffering 
from sickle cell disease and chronic renal failure (14) 
due to an exaggerated response to the increase in 
preload. These examples challenge the embryogenesis 
theory and suggest involvement of acquired pathogenetic 
mechanisms or epigenetic factors. Given these 
considerations a recent review recommends cautious 
diagnostic labeling of LVNC as a cardiomyopathy (15). 
Genetics 
LVNC is a heterogeneous, familial, or sporadic 
genetic disorder. Genetic studies have strongly 
suggested that the disease has a pattern of inheritance 
(18% to 50% of cases are familial). The family form 
appears more frequently in adults with isolated LVNC 
than in the case of children, and it can be autosomal 
dominant, X-linked, or mitochondrial. Mutations of 
genes that code sarcomeric proteins (ACTC1 - cardiac 
alpha actinin, MYH7 - beta myosin heavy chain, TNNT2 
- Troponin T, G4.5-tafazzin - responsible for Barth 
syndrome, TMP1-tropomyosin, MYBPC3 - binding 
protein C) (16-18), cytoskeletal and Z-line components 
(LDB3 - binding protein 3) (19), nuclear envelope 
proteins (LMNA-laminin A/C) (20) and ion-channels 
(SNC5A - RYR2) (21) have been identified in patients 
with ventricular non-compaction. Moreover, the 
hypertrabecular and non-compacted aspect of the left 
ventricle has also been associated with monogenic 
syndromes such as Danon disease (22) or, in a few cases, 
Anderson-Fabry disease (23). Other genetic conditions 
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that coexist with the spongious feature of the LV 
myocardium are Duchenne muscular dystrophy (24), 
mitochondrial myopathies (9), chromosomal disorders, 
and congenital heart disease. Specific mutations in genes 
of the Notch1 pathway (mindbomb homolog 1) in mice 
and humans leading to dysregulated signaling and 
hypertrabeculation and non-compaction (25), as well as 
mutations in the G4.5 gene that result in a severe, 
infantile, X-linked form of LVNC, suggest strongly that 
LVNC is a cardiomyopathy. 
It is therefore both important and challenging to 
distinguish whether LVNC is an isolated 
cardiomyopathy or an anatomical characteristic 
associated with other cardiac disorders. Previous studies 
suggest that a detailed analysis of the family background 
in patients diagnosed with LVNC is justified. 
Physiopathology 
The two myocardial layers and the trabeculae are 
vascularized by the epicardial coronary arteries and the 
intertrabecular recesses receive blood from the 
ventricular cavity.  Endocardial hypoperfusion arises 
because of a discrepancy between the number of 
capillaries and the myocardial mass. As a consequence 
of ischemia, fibrosis will expand progressively and will 
ultimately determine left ventricular systolic function 
depression which will predispose to ventricular 
arrhythmias. LVNC is a potential thromboembolic 
disease due to the blood stagnation in the intertrabecular 
recesses which predisposes to clot formation, which can 
embolize in systemic circulation. 
Imaging and Diagnosis 
A multimodal diagnostic approach is the current 
recommendation for LVNC diagnosis. 
Echocardiography, although dependent on the 
echocardiographer’s skills and the echocardiographic 
window, remains the primary diagnostic method. Other 
imaging methods such as cardiac MRI can diagnose the 
pathology, when echocardiographic examination is 
suboptimal.  
Echocardiographic diagnosis criteria 
Transthoracic bidimensional echocardiography (2D-
TTE) is the method of choice for diagnosing LVNC 
(Figure 2-4). Three basic echocardiographic criteria have 
been proposed to define LVNC: a thick myocardium 
with a non-compacted layer and a compacted one; 
prominent trabeculations; and deep endomyocardial 
recesses.    
Several echocardiographic derived algorithms for 
diagnosing LVNC have been proposed (3, 26, 27). The 
first echocardiographic criterion has defined ventricular 
wall non-compaction as the ratio X / Y < 0.5, where X 
represents the distance from the epicardial surface to the 
trabecular recesses and Y is the distance from the 
epicardial surface to the peak of trabeculae, measured in 
parasternal short axis for the apex and apical sections for 
the left ventricular free wall (3). Others have proposed a 
ratio between non-compacted and compacted 
myocardium greater than 2:1 at end systole, in apical 
short axis section, in the absence of other cardiac 
disorders (26) for the diagnosis of LVNC. The 
trabeculae are usually situated at the apex / lateral wall, 
medium wall / inferior wall of the left ventricle. Most of 
the non-compacted segments are hypokinetic. 
Stollberger et al. (27) defined LVNC as the presence of 
more than three trabeculae in the left ventricular wall, 
with trabeculae situated at the apex, visible in a single 
imaging plan. The flow between the inter-trabecular 
recesses can be identified by using the color Doppler 
method. A fourth criterion has been proposed by 
Belanger et al. (28), who diagnosed LVNC using 
planimetric echocardiography to measure the trabeculae 
in apical 4 chambers section. They divided the patients 
by the area of left ventricular non-compaction into 3 
groups: mild (< 2.5 cm2), moderate (2.5-4.9 cm2) and 
severe (> 5 cm2). Based on a study on 380 patients, 
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15.8% were diagnosed with LVNC. However, their 
criteria have not been validated as there was no 
correlation with the modified Jenni et al. criteria. 
 
 
Figure 2. Bidimensional transthoracic echo-
cardiography, short axis view of the left ventricle apex. 
Note the excessive trabeculation in the infero-postero-
lateral region. Red line indicates the distance from the 
epicardial line to the beginning of the trabeculae (7 mm) 
and yellow line marks the thickness of the trabeculae 
(17 mm). 
 
Figure 3. Bidimensional transthoracic echo-
cardiography, apical 3-chamber view (the same patient 
as in figure 2). The hypertrabeculation can be observed 
in the mid and apical region of the posterior wall 
(yellow arrows). 
Newer echocardiographic techniques such as tissue 
Doppler imaging, strain rate imaging, and speckle 
tracking imaging are now available for the diagnosis of 
LVNC. Global longitudinal strain was found to be lower 
in subjects with LVNC compared with healthy controls 
even in the presence of normal systolic/diastolic function 
(29). A recent study also demonstrated that while in 
normal individuals and subjects with hypertrophic 
cardiomyopathy there is a significant increase in 
longitudinal deformation from base to apex, in subjects 
with LVNC, apical strain was only mildly and not 
significantly increased (30). Three-dimensional 
echocardiography and contrast echocardiography may 
bring additional valuable data to the dimensional 
assessment in patients with LVNC by providing an 
accurate evaluation of the number of trabeculae, 
compacted segments, and intertrabecular recesses (31). 
 
 
Figure 4. Speckle tracking echocardiography analysis, 
bull’s eye and regional strain curves (the same patient as 
in figure 2). Mildly decreased global longitudinal strain, 
with a value of -16.2%. Deformation is lower in the 
basal segments and normal in the midwall and apical 
segments. This may be explained by the globular shape 
of the LV and the presence of trabeculae in the apex. 
Cardiac Magnetic Resonance criteria 
Cardiac magnetic resonance imaging is continually 
evolving and may contribute to a more accurate 
identification of LVNC.  Cardiac MRI is particularly 
useful in patients in whom the apex is difficult to 
visualize with echocardiography. Two sets of MRI 
criteria proposed by Petersen in 2005 (32) and Jacquier 
in 2010 (33) are used for LVNC diagnosis. Petersen et 
al. defined a ratio between non-compacted/compacted 
layer > 2.3 measured in end-diastole as a cutoff for 
LVNC. Jacquier et al. calculated the LV trabecular mass 
in short axis views in end-diastole and concluded that a 
trabecular mass > 20% was predictive for LVNC. 
Captur and al. (34) described a recent cardiac MRI 
technique, based on fractal analysis, which does not rely 
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on ‘classical’ compacted/non-compacted ratio. A fractal 
dimension > 1.3 gave the optimal prediction for LVNC. 
Late gadolinium enhancement (LGE) of trabeculae 
has also been observed in LVNC. LGE distributions in 
patients fulfilling LVNC criteria can be very 
heterogeneous, which may suggest several distinct 
cardiomyopathic processes that are responsible for 
LVNC. Small areas of myocardial fibrosis have also 
been observed in patients with preserved systolic 
function (35). 
Other diagnostic imaging  
Computed tomography (CT) is an alternative 
method of diagnosing LVNC if the echocardiogram is 
non-diagnostic or unavailable (36). Positron emission 
tomography (PET), which quantitatively evaluates 
myocardial blood flow and coronary flow reserve, may 
be used to assess microcirculatory dysfunction 
ultimately responsible for the wall motion abnormalities 
(37).  
Differential diagnosis  
As there is no diagnostic gold standard, LVNC is 
frequently underdiagnosed or misdiagnosed as 
hypertrophic or dilated cardiomyopathy. The differential 
diagnosis should include: apical hypertrophic 
cardiomyopathy, left ventricular hypertrophy, dilated 
cardiomyopathy, arrhythmogenic left ventricular 
dysplasia, myocardial/endocardial fibroelastosis, cardiac 
tumors, left ventricular apical thrombus, normal heart 
with left ventricular prominent trabeculations (less than 
3 trabeculations in echocardiography). Usually, a careful 
echocardiography study by a trained examiner will 
provide the diagnosis. A major challenge is to 
differentiate LVNC with dilated left ventricle from 
dilated cardiomyopathy. 
Management of LVNC 
Currently no specific guidelines exist for the 
treatment of LVNC. Clinical management of LVNC 
depends on the presence or absence of cardiac 
dysfunction or arrhythmias. Patients with normal LV 
size and function will undergo clinical monitoring, 
whereas symptomatic patients with LV dilation and 
dysfunction or hypertrophy may be managed according 
to their clinical needs and corresponding guidelines. In 
later stages, recommendations for treatment follow the 
international guidelines of heart failure management. 
Treatment usually requires the combination of beta-
blockers, ACE inhibitors/ARB, diuretics, and 
aldosterone antagonists. 
The main complications related to LVNC are 
systemic thromboembolic events, arrhythmias, 
progressive heart failure, and sudden cardiac death. Oral 
anticoagulation is a debated issue in the prevention of 
thromboembolic complications. The question that arises 
is whether anticoagulation should be given 
independently of arrhythmias or LV dysfunction for 
primary prevention of embolic episodes, or only in the 
presence of LV dysfunction, arrhythmias, prior embolic 
events, or proven atrial or ventricular thrombi. Left 
ventricular clot and documented atrial fibrillation are 
clear situations when oral anticoagulation should be 
used. For patients that do not fall into either of these 
categories, Bennet et al. suggest a risk assessment using 
the CHADS2/CHA2DS2-Vasc scores as guidance and a 
discussion with the patient regarding the risks and 
benefits of anticoagulation (38). 
Sudden cardiac death is another concerning 
complication of LVNC. Patients should be periodically 
evaluated by Holter ECG for ventricular arrhythmias. 
The incidence of ventricular arrhythmias rises from 2% 
to 62% in patients with LVNC. Those with sustained 
ventricular arrhythmia and those who have experienced 
an episode of cardiac arrest require ICD implantation. 
Although data regarding anti-arrhythmic therapy are 
scant, recent research supports the idea of early 
aggressive therapy, including defibrillator and evaluation 
for cardiac transplant, for patients with bundle brunch 
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block, increased left ventricle end-diastolic diameter, or 
permanent or persistent atrial fibrillation in III-IV 
NYHA functional class. 
Echocardiographic screening is also recommended 
for family members, given that the symptoms are 
variable and the risks include heart failure and sudden 
cardiac death. Genetic testing for LVNC does not change 
clinical management of the disease; however, it may be 
helpful for confirming diagnosis in family members. 
Prognosis 
LVNC is associated with high morbidity and 
mortality rates although prognosis has significantly 
improved in recent years through earlier diagnosis and 
use of heart failure medications and device therapy. In 
one Swiss cohort, 35% of patients suffered early death, 
53% required hospitalization for congestive heart failure, 
41% had ventricular tachyarrhythmia, 12% required 
ICDs, and 12% required heart transplantation over 44 
months of follow-up (39). In another recent study, 
among 45 patients referred to a cardiomyopathy center, 
survival free of transplantation was 97% over 4 years of 
follow-up (40). 
 
Conclusions 
LVNC is a rare cardiomyopathy associated with 
significant morbidity and mortality. The diagnosis 
remains challenging and a multimodal diagnostic 
approach is currently recommended. The classical 
clinical presentation is the triad of heart failure, 
arrhythmias, and embolic events. There are no consensus 
guidelines for the management of these patients. 
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